Edwards Lifesciences Corp (EW)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	1,402,400	1,430,900	1,389,500	1,488,800	1,521,900	1,458,800	1,455,400	1,538,500	1,503,100	2,063,200	2,048,300	1,436,900	1,409,300	1,401,800	1,351,300	1,715,500	1,654,600	1,689,700	1,640,900	1,681,300
Total assets	US$ in thousands	9,363,200	9,370,800	9,004,000	8,651,200	8,292,500	8,638,200	8,425,100	8,419,900	8,502,600	8,160,300	7,662,100	7,213,700	7,237,100	6,800,800	6,424,100	6,076,100	6,488,100	5,966,300	5,573,500	5,469,300
ROA		14.98%	15.27%	15.43%	17.21%	18.35%	16.89%	17.27%	18.27%	17.68%	25.28%	26.73%	19.92%	19.47%	20.61%	21.03%	28.23%	25.50%	28.32%	29.44%	30.74%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $1,402,400K ÷ $9,363,200K
= 14.98%

Edwards Lifesciences Corp's Return on Assets (ROA) has displayed variability over the past eight quarters, ranging from a low of 14.98% in Q4 2023 to a high of 18.35% in Q4 2022. The company's average ROA during this period was 16.75%, indicating its ability to generate profits relative to its total assets.

A higher ROA suggests that Edwards Lifesciences Corp is efficiently utilizing its assets to generate earnings. However, the declining trend in ROA from Q4 2022 to Q4 2023 may indicate potential challenges in asset management or declining profitability relative to total assets.

It is essential for investors and stakeholders to monitor Edwards Lifesciences Corp's ROA closely to assess the company's operational efficiency and financial performance, as changes in this metric can reflect the company's ability to generate profits from its asset base.